Chronic inflammation is strongly associated with cancer development, so cancer can be clinically treated with drugs that neutralize pro‐inflammatory cytokines or target their receptors.[143, 144, 145] The pro‐inflammatory cytokine IL‐2 enhances the antitumor capacity of chimeric antigen receptor T cells, helping them to overcome the resistance to PD‐1 and cytotoxic T lymphocyte antigen 4 (CTLA‐4).[146, 147] This is because the antitumor immune capacity of many cancer patients is in a “cold” state, and inflammation activates it. Here, CTLA4 is linked to cancer.